Sibutramine is a Medicine belongs to Anti-Obesity group whose information about Brand can be referenced from   Book : Martindale    Page : 2330   Edition : 38  

  ►   Brandname : Meridia, Reductil, Fetrasil, Leptos, Obestat
  ►  Strength :

A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 2164   Edition : 36  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Obesity Oral 10 mg taken in the morning. Patients who cannot tolerate 10 mg daily may benefit from a dose of 5 mg daily.

Ref :-  Book : Martindale    Page : 2164   Edition : 36  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :    Page :    Edition :   
►  Side Effect : Vasodilatation, Cardiac arrhythmias, Hypertension, Myocardial infarction, Stroke
Ref :-   Book : Martindale    Page : 2330   Edition : 38.  

►  Drug Interaction : Drug interaction of Sibutramine is with Monoamine Oxidase Inhibitor, selective serotonin reuptake inhibitors, , Alcohol,  Sumatriptan , Lithium carbonate , Pethidine/Meperidine , Fentanyl, Dextromethorphan , Pentazocine , Ephedrine , Phenylpropanolamine, Pseudoephedrine, Ketoconazole , Erythromycin , Rifampicin , Phenytoin , Carbamazapine , Phenobarbital
Ref :-   Book : Martindale    Page : 2163   Edition : 36.  

  ►    Mechanism of Drug Drug Interaction :  Sibutramine should not be given with, or within at least 2 weeks of stopping an MAOI; at least 2 weeks should elapse between discontinuation of sibutramine and starting therapy with an MAOI. There is a risk of the serotonin syndrome developing if sibutramine is used with other serotonergic drugs such as SSRIs, sumatriptan, lithium, pethidine, fentanyl, dextromethorphan, and pentazocine. Caution is advised when sibutramine is given with other drugs that may increase heart rate or blood pressure such as ephedrine, phenylpropanolamine, and pseudoephedrine. It should not be used with other centrally acting anorectics. Alcohol should be avoided. Inhibitors of the cytochrome P450 isoenzyme CYP3A4, such as ketoconazole and erythromycin, may increase plasma concentrations of sibutramine. Conversely, inducers of this isoenzyme, such as rifampicin, phenytoin, carbamazepine, and phenobarbital, may reduce plasma concentrations of sibutramine.
Ref :-   Book : Martindale    Page : 2163   Edition : 36.  

►  Contraindication : Patients with a history of eating disorders such as anorexia nervosa and bulimia nervosa, Patients with uncontrolled or poorly controlled hypertension and should be used with caution in patients with a history of, or with, well-controlled hypertension, Patients with a history of cerebrovascular disease or cardiovascular disorders such as cardiac arrhythmias, heart failure, peripheral arterial occlusive disease, and coronary artery disease., Patients with severe hepatic or renal impairment, With mild to moderate renal impairment., In patients with bipolar disorder, Tourette’s syndrome, hyperthyroidism, phaeochromocytoma, benign prostatic hyperplasia, or a history of drug or alcohol abuse. It should be used with caution, if at all, in patients with glaucoma, Patients with a history of depression, seizures or gallstones (which may be precipitated or exacerbated by weight loss), or a family history of motor or verbal tics., Patients should not drive or operate machinery.
Ref :-   Book : Martindale    Page : 2163   Edition : 36.  
  ►  Mechanism of Action :   Sibutramine is a serotonin and noradrenaline reuptake inhibitor; it also inhibits dopamine reuptake but to a lesser extent.
Ref :-   Book : Martindale    Page : 2330   Edition : 38.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- 5 HTP(5-HYDROXYTRYPTOPHAN) with Causes serotonin syndrome ..   EPHEDRA with increased blood pressure ..  

  ►  Reference :-
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press

  •   ►  URL --

    ►   Route of Elimination :   Faecal, Hepatic (Metabolism), Renal
    Ref :-   Book : Martindale    Page : 2163   Edition : 36.  

    ►    Plasma Half-life :   Min value :-   14 hours,    Max value :-   16 hours.  
    Ref :-   Book : Martindale    Page : 2163   Edition : 36.  

    ►    Peak Plasma Concentration :   Min value :-   appear after 1.2 hours (parent drug) and 3 to 4 hours (metabolites).,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 2163   Edition : 36.